Zolgensma (onasemnogene abeparvovec) — Spinal Muscular Atrophy gene therapy
Customize your policy alerts
Sign up for Cigna Policy IP0185 alerts
Get alerted when Policy IP0185 changes without checking for updates manually.
Monitor payer policy activity
Cigna coverage policy governing prior authorization, medical necessity criteria, dosing, and documentation for one-time intravenous Zolgensma in patients with spinal muscular atrophy under 2 years of age.
Changed prior-use verification language to require verification in claims history that patient has not received Zolgensma; if claims not available, prescribing physician must confirm no prior receipt.
Updated premature neonate requirement to full-term gestation age of 39 weeks and 0 days (postmenstrual age ≥ 39 weeks and 0 days).
Added requirement that current patient body weight be obtained within the past 14 days [documentation required].
If criteria A through N are met, approve one-time (per lifetime) single dose of 1.1 x 10^14 vg/kg IV; Zolgensma is provided as customized kits by weight (kit sizes listed in Table 2).
Added 'Policy Statement' and a documentation requirement specifying documentation may include chart notes, lab results, claims records, prescription receipts, and other information.
Added note that pathogenic variants may include homozygous deletion, compound heterozygous mutation, or other rare mutations for confirming bi-allelic SMN1 pathogenic variants.
Coverage and Medical Necessity Criteria
Initial (FDA-Approved) Therapy
Covered when ALL of the following are met
All subcriteria A–N must be met for approval
Initial Therapy
Approve one dose when ALL of the following are met:
Documentation required where indicated
Initial therapy (one-time gene therapy authorization)
Approve for a one-time (per lifetime) single dose if ALL of the following are met:
Full node-level detail A–N is located in the policy sections cited; documentation required where noted.
Use of Zolgensma in patients with advanced spinal muscular atrophy (for example, complete paralysis of limbs or permanent ventilator dependence) has not been assessed and therefore is not supported by evidence of safety or effectiveness for these populations. Prior to infusion, evaluate baseline liver function and other labs because Zolgensma carries a boxed warning for acute serious liver injury and acute liver failure, and patients with preexisting liver impairment may be at higher risk.
Administration of Zolgensma will not be approved for patients meeting the policy’s listed limitation-of-use populations, including those with complete paralysis of all limbs or permanent ventilator dependence. If the patient is currently receiving other disease-modifying SMA therapies (e.g., nusinersen [Spinraza] or risdiplam [Evrysdi]), the prescribing physician must confirm those therapies will be discontinued before Zolgensma approval is granted.
Administration of Zolgensma in utero is explicitly not recommended for approval and is listed among the policy’s conditions not covered; Zolgensma is not approved for in utero administration per the prescribing information.
If the patient has a history of prior gene therapy (including Zolgensma or Itvisma), this is a basis for non-approval. The policy requires verification in claims history that the patient has not previously received Zolgensma or Itvisma; when no claims history is available, the prescribing physician must confirm the patient has not previously received these gene therapies.
Claims for services billed with diagnosis or procedure codes that are not covered under this policy will be denied as not covered. Providers must submit claims using the covered codes referenced in the policy and include the required documentation to avoid denial.
Use of Zolgensma for any indication or patient population that does not meet the policy’s specified criteria is considered not medically necessary. This includes the limitation-of-use populations listed under Conditions Not Covered.
Prior receipt of any gene therapy (listed under the policy’s Conditions Not Recommended for Approval) is treated as a condition for which Zolgensma is not medically necessary and may result in denial of coverage.
Coding, Dosing, and Clinical Thresholds
| NDCs listed in Table 2 | Zolgensma kit sizes per NDC for weight-based dosing (Table not included in this part) |
| J3399 | Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5 x 10^15 vector genomes |
Prior Authorization, Documentation, and Administrative Requirements
Prior authorization required (one-time dose, 90-day duration)
Prior authorization is required for Zolgensma; approvals are granted one time (per lifetime) for a single intravenous dose and the authorization duration is 90 days to allow preparation and administration.
PA required for one-time IV Zolgensma (J3399) at 1.1 x 10^14 vg/kg
Prior authorization must be obtained to approve one lifetime IV dose of Zolgensma (HCPCS J3399) dosed at 1.1 x 10^14 vector genomes per kg; approval is tied to documented criteria and verification of the appropriate weight‑based kit NDC.
Approve one dose only if all criteria A–N are met
Approve a single one‑time (per lifetime) dose only if all criteria A through N in the policy are met; verification of documentation and appropriate weight‑based dosing is required by a Medical Director.
Verify no prior gene therapy (claims or prescriber confirmation)
Verify claims history to confirm the patient has not previously received Zolgensma or Itvisma; if claims history is unavailable or contains no record, the prescribing physician must confirm no prior receipt.
Prescriber must confirm discontinuation of Spinraza or Evrysdi
If the patient is receiving or has received Spinraza (nusinersen) or Evrysdi (risdiplam), the prescribing physician must confirm that those therapies will be discontinued prior to Zolgensma approval.
Confirm discontinuation of other SMA therapies before Zolgensma
Prescriber confirmation is required that alternative disease‑modifying SMA therapies (nusinersen/Spinraza or risdiplam/Evrysdi) will be discontinued before administration of Zolgensma.
Prescriber confirmation required to discontinue other SMA therapies
Prescribing physician must confirm that any other SMA disease‑modifying therapies (e.g., Spinraza or Evrysdi) will be discontinued prior to Zolgensma administration; this confirmation is required as part of the authorization documentation.
Evrysdi availability updated (tablets) — referenced for prior therapy verification
Note that Evrysdi (risdiplam) is referenced in the policy with updated availability to include tablets; this is noted in the context of required discontinuation/verification of prior therapies.
Required documentation for prior authorization (genetics, labs, weight, prior‑use)
Provide documentation as noted in the criteria: genetic testing confirming bi‑allelic SMN1 pathogenic variants, SMN2 copy number (and quantitative assay when required), baseline anti‑AAV9 titers, recent liver and renal function tests, CBC, current body weight, and verification of no prior gene therapy.
- Genetic test confirming bi‑allelic SMN1 pathogenic variants [documentation required].
- SMN2 copy number testing; quantitative assay required if 4 copies [documentation required].
- Baseline anti‑AAV9 titers ≤ 1:50 [documentation required].
- Liver function tests, prothrombin time within past 30 days [documentation required].
- Renal function (creatinine < 1.0 mg/dL within past 30 days) [documentation required].
- CBC (WBC ≤ 20,000 and hemoglobin within normal range within past 30 days) [documentation required].
- Current body weight obtained within past 14 days [documentation required].
- Verification that patient has not previously received Zolgensma or Itvisma (claims or prescriber confirmation).
Attach chart notes, labs, test reports, claims/prescription records as documentation
Where criteria indicate [documentation required], include chart notes, laboratory results, medical test results, claims records, prescription receipts, and other relevant records with patient identifiers to support the request.
Permitted forms of documentation for [documentation required] items
Documentation may include chart notes, laboratory results, medical test results, claims records, prescription receipts, and/or other information as specified in the criteria to support eligibility and dosing verification.
Provide current body weight (within 14 days)
Current patient body weight must be documented within the past 14 days and included with the prior authorization request to permit weight‑based dose calculation and kit selection.
Claims require covered codes and required documentation or they will be denied
Claims submitted without the covered diagnosis/procedure code(s) (per policy) or lacking the required supporting documentation will be denied as not covered.
Conditions Not Covered may lead to denial (advanced disease, ventilator dependence, in utero)
Requests for Zolgensma for conditions listed under 'Conditions Not Covered' — such as complete paralysis of all limbs, permanent ventilator dependence, in utero administration, or other limitations — will be considered not medically necessary and may be denied.
Initial One-Time Dosing Criteria
Initial Therapy — Initial one-time dosing criteria (top-level criteria set)
Initial one-time dosing criteria
Documentation and verification required as noted
Initial Therapy — Initial coverage requires ALL of the following
Initial coverage requires ALL of the following
Documentation required where indicated
Initial Therapy (one-time infusion) — Initial one-time treatment criteria to approve single infusion
Initial one-time treatment — approve single infusion when ALL criteria are met
Refer to Table 2 for kit NDCs and to policy A–N criteria for full details; documentation required where noted.
Step Therapy and Therapy Sequencing
| Step | Requirement | Coverage |
|---|---|---|
| 1 | If patient is currently receiving Spinraza (nusinersen) or Evrysdi (risdiplam), the prescribing physician must confirm those therapies will be discontinued prior to approval of Zolgensma. | Prescriber confirmation required prior to approval |
| Step | Prescriber Action | Coverage |
|---|---|---|
| 1 | Prescriber must confirm discontinuation of alternative SMA disease‑modifying therapies (Spinraza or Evrysdi) if the patient is currently receiving them before Zolgensma is approved. | Confirmation required; approval contingent on documentation |
| Note | Detail | Coverage Implication |
|---|---|---|
| Policy reference to other SMA therapies | The policy references prior or concurrent use of other SMA therapies (e.g., Evrysdi available as oral solution and tablets) and requires prescriber confirmation that such therapies will be discontinued when applicable; the excerpt does not mandate a specific step‑failure sequence. | Referenced therapies do not imply mandated step sequencing in this excerpt |
Quantity Limits and Dispensing
Administration Setting and Provider Qualifications
Prescriber should specialize or consult in SMA/neuromuscular care
Zolgensma administration requires specialized skills and training; the prescribing physician should have consulted with or specialize in SMA/neuromuscular disorders prior to requesting authorization.
Intravenous administration and kit NDCs required
Administration is by intravenous infusion; approval is linked to weight‑based kit sizes with specific NDCs (kits listed in Table 2) that must be verified for authorization.
Administration by IV infusion (hospital outpatient)
Administration is performed by IV infusion in a hospital outpatient setting; site‑of‑care specifics are not detailed in this excerpt but require appropriate infusion capabilities.
Background and Clinical Context
Spinal muscular atrophy (SMA) is an autosomal recessive, progressive neuromuscular disorder caused by biallelic pathogenic variants in the SMN1 gene, which result in reduced survival motor neuron (SMN) protein and loss of motor neurons. Clinical severity is influenced by SMN2 copy number. Zolgensma is an adeno-associated virus (AAV)-based, single-dose intravenous gene replacement therapy indicated for SMA due to bi-allelic SMN1 mutations in patients less than 2 years of age. Safety of repeat administration and use in advanced disease states has not been established.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.